Lamivudine/Maraviroc/Zidovudine
- Generic Name
- Lamivudine/Maraviroc/Zidovudine
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus I
- Interventions
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT01597648
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath